Myelopathy following intrathecal chemotherapy in adults: a single institution experience

David Cachia, Carlos Kamiya-Matsuoka, Chelsea C. Pinnix, Linda Chi, Hagop M. Kantarjian, Jorge E. Cortes, Naval Daver, Karin Woodman

Research output: Contribution to journalArticle

Abstract

Methotrexate and cytarabine arabinoside are frequently administered intrathecally in the prophylaxis and treatment of patients with hematological malignancies. Myelopathy as a complication of intrathecal (IT) chemotherapy is rare in adults, with most of the cases described in the literature occurring in the pediatric population. Between January 2010 and March 2014, 587 newly diagnosed B cell acute lymphoblastic leukemia and 24 chronic myeloid leukemia lymphoid blast phase patients were seen at The University of Texas MD Anderson Cancer Center. This case series discusses seven adult cases deemed to have IT chemotherapy-induced myelopathy between 2010 and 2014 at MD Anderson Cancer Center. Five out of the seven patients had T2 abnormalities involving the dorsal columns of the spinal cord. An elevated myelin basic protein level was noted in the two patients in whom it was checked. The wide range of dosage and timing with respect to IT chemotherapy administration suggests an idiosyncratic reaction or individual threshold to the development of myelopathy. By describing the largest case series of myelopathy in adults, we aim to raise awareness about this rare albeit devastating complication. Based on the seven cases described we would recommend—MRI of the spine with T2-weighted imaging in the sagittal and axial planes in leukemia patients with unexplained myelopathy and consideration to delay IT chemotherapy until after an extensive work-up to rule out CNS leukemia. Though more data are needed on the use of folate metabolites, preliminary results have shown some promise in the treatment of methotrexate-induced myelopathy and may be a potential consideration for future patients suspected to have chemotherapy induced myelopathy.

Original languageEnglish (US)
Pages (from-to)391-398
Number of pages8
JournalJournal of Neuro-Oncology
Volume122
Issue number2
DOIs
StatePublished - Apr 1 2015
Externally publishedYes

Fingerprint

Spinal Cord Diseases
Drug Therapy
Methotrexate
Leukemia
Blast Crisis
Myelin Basic Protein
Cytarabine
Hematologic Neoplasms
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Folic Acid
Neoplasms
Spinal Cord
Spine
B-Lymphocytes
Pediatrics
Therapeutics
Population

Keywords

  • Intrathecal chemotherapy
  • Lymphoid leukemia
  • Myelopathy
  • Spinal cord dorsal columns T2 hyperintensity

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this

Cachia, D., Kamiya-Matsuoka, C., Pinnix, C. C., Chi, L., Kantarjian, H. M., Cortes, J. E., ... Woodman, K. (2015). Myelopathy following intrathecal chemotherapy in adults: a single institution experience. Journal of Neuro-Oncology, 122(2), 391-398. https://doi.org/10.1007/s11060-015-1727-z

Myelopathy following intrathecal chemotherapy in adults : a single institution experience. / Cachia, David; Kamiya-Matsuoka, Carlos; Pinnix, Chelsea C.; Chi, Linda; Kantarjian, Hagop M.; Cortes, Jorge E.; Daver, Naval; Woodman, Karin.

In: Journal of Neuro-Oncology, Vol. 122, No. 2, 01.04.2015, p. 391-398.

Research output: Contribution to journalArticle

Cachia, D, Kamiya-Matsuoka, C, Pinnix, CC, Chi, L, Kantarjian, HM, Cortes, JE, Daver, N & Woodman, K 2015, 'Myelopathy following intrathecal chemotherapy in adults: a single institution experience', Journal of Neuro-Oncology, vol. 122, no. 2, pp. 391-398. https://doi.org/10.1007/s11060-015-1727-z
Cachia, David ; Kamiya-Matsuoka, Carlos ; Pinnix, Chelsea C. ; Chi, Linda ; Kantarjian, Hagop M. ; Cortes, Jorge E. ; Daver, Naval ; Woodman, Karin. / Myelopathy following intrathecal chemotherapy in adults : a single institution experience. In: Journal of Neuro-Oncology. 2015 ; Vol. 122, No. 2. pp. 391-398.
@article{f12795f1384b4159a249b00fc1353c5e,
title = "Myelopathy following intrathecal chemotherapy in adults: a single institution experience",
abstract = "Methotrexate and cytarabine arabinoside are frequently administered intrathecally in the prophylaxis and treatment of patients with hematological malignancies. Myelopathy as a complication of intrathecal (IT) chemotherapy is rare in adults, with most of the cases described in the literature occurring in the pediatric population. Between January 2010 and March 2014, 587 newly diagnosed B cell acute lymphoblastic leukemia and 24 chronic myeloid leukemia lymphoid blast phase patients were seen at The University of Texas MD Anderson Cancer Center. This case series discusses seven adult cases deemed to have IT chemotherapy-induced myelopathy between 2010 and 2014 at MD Anderson Cancer Center. Five out of the seven patients had T2 abnormalities involving the dorsal columns of the spinal cord. An elevated myelin basic protein level was noted in the two patients in whom it was checked. The wide range of dosage and timing with respect to IT chemotherapy administration suggests an idiosyncratic reaction or individual threshold to the development of myelopathy. By describing the largest case series of myelopathy in adults, we aim to raise awareness about this rare albeit devastating complication. Based on the seven cases described we would recommend—MRI of the spine with T2-weighted imaging in the sagittal and axial planes in leukemia patients with unexplained myelopathy and consideration to delay IT chemotherapy until after an extensive work-up to rule out CNS leukemia. Though more data are needed on the use of folate metabolites, preliminary results have shown some promise in the treatment of methotrexate-induced myelopathy and may be a potential consideration for future patients suspected to have chemotherapy induced myelopathy.",
keywords = "Intrathecal chemotherapy, Lymphoid leukemia, Myelopathy, Spinal cord dorsal columns T2 hyperintensity",
author = "David Cachia and Carlos Kamiya-Matsuoka and Pinnix, {Chelsea C.} and Linda Chi and Kantarjian, {Hagop M.} and Cortes, {Jorge E.} and Naval Daver and Karin Woodman",
year = "2015",
month = "4",
day = "1",
doi = "10.1007/s11060-015-1727-z",
language = "English (US)",
volume = "122",
pages = "391--398",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Myelopathy following intrathecal chemotherapy in adults

T2 - a single institution experience

AU - Cachia, David

AU - Kamiya-Matsuoka, Carlos

AU - Pinnix, Chelsea C.

AU - Chi, Linda

AU - Kantarjian, Hagop M.

AU - Cortes, Jorge E.

AU - Daver, Naval

AU - Woodman, Karin

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Methotrexate and cytarabine arabinoside are frequently administered intrathecally in the prophylaxis and treatment of patients with hematological malignancies. Myelopathy as a complication of intrathecal (IT) chemotherapy is rare in adults, with most of the cases described in the literature occurring in the pediatric population. Between January 2010 and March 2014, 587 newly diagnosed B cell acute lymphoblastic leukemia and 24 chronic myeloid leukemia lymphoid blast phase patients were seen at The University of Texas MD Anderson Cancer Center. This case series discusses seven adult cases deemed to have IT chemotherapy-induced myelopathy between 2010 and 2014 at MD Anderson Cancer Center. Five out of the seven patients had T2 abnormalities involving the dorsal columns of the spinal cord. An elevated myelin basic protein level was noted in the two patients in whom it was checked. The wide range of dosage and timing with respect to IT chemotherapy administration suggests an idiosyncratic reaction or individual threshold to the development of myelopathy. By describing the largest case series of myelopathy in adults, we aim to raise awareness about this rare albeit devastating complication. Based on the seven cases described we would recommend—MRI of the spine with T2-weighted imaging in the sagittal and axial planes in leukemia patients with unexplained myelopathy and consideration to delay IT chemotherapy until after an extensive work-up to rule out CNS leukemia. Though more data are needed on the use of folate metabolites, preliminary results have shown some promise in the treatment of methotrexate-induced myelopathy and may be a potential consideration for future patients suspected to have chemotherapy induced myelopathy.

AB - Methotrexate and cytarabine arabinoside are frequently administered intrathecally in the prophylaxis and treatment of patients with hematological malignancies. Myelopathy as a complication of intrathecal (IT) chemotherapy is rare in adults, with most of the cases described in the literature occurring in the pediatric population. Between January 2010 and March 2014, 587 newly diagnosed B cell acute lymphoblastic leukemia and 24 chronic myeloid leukemia lymphoid blast phase patients were seen at The University of Texas MD Anderson Cancer Center. This case series discusses seven adult cases deemed to have IT chemotherapy-induced myelopathy between 2010 and 2014 at MD Anderson Cancer Center. Five out of the seven patients had T2 abnormalities involving the dorsal columns of the spinal cord. An elevated myelin basic protein level was noted in the two patients in whom it was checked. The wide range of dosage and timing with respect to IT chemotherapy administration suggests an idiosyncratic reaction or individual threshold to the development of myelopathy. By describing the largest case series of myelopathy in adults, we aim to raise awareness about this rare albeit devastating complication. Based on the seven cases described we would recommend—MRI of the spine with T2-weighted imaging in the sagittal and axial planes in leukemia patients with unexplained myelopathy and consideration to delay IT chemotherapy until after an extensive work-up to rule out CNS leukemia. Though more data are needed on the use of folate metabolites, preliminary results have shown some promise in the treatment of methotrexate-induced myelopathy and may be a potential consideration for future patients suspected to have chemotherapy induced myelopathy.

KW - Intrathecal chemotherapy

KW - Lymphoid leukemia

KW - Myelopathy

KW - Spinal cord dorsal columns T2 hyperintensity

UR - http://www.scopus.com/inward/record.url?scp=84940001508&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940001508&partnerID=8YFLogxK

U2 - 10.1007/s11060-015-1727-z

DO - 10.1007/s11060-015-1727-z

M3 - Article

C2 - 25666482

AN - SCOPUS:84940001508

VL - 122

SP - 391

EP - 398

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 2

ER -